These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 23036337)

  • 1. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
    Shimazawa R; Ikeda M
    Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of drug-approval regulations for medical countermeasures against CBRN agents in Japan.
    Shimazawa R; Ikeda M
    Health Secur; 2015; 13(2):130-8. PubMed ID: 25813978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects.
    Nagai S; Ozawa K
    Invest New Drugs; 2016 Dec; 34(6):777-791. PubMed ID: 27538583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.
    Sridhara R; Johnson JR; Justice R; Keegan P; Chakravarty A; Pazdur R
    J Natl Cancer Inst; 2010 Feb; 102(4):230-43. PubMed ID: 20118413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Off-label use of drugs--the legal framework].
    Koyuncu A
    Dtsch Med Wochenschr; 2012 Jul; 137(30):1519-23. PubMed ID: 22869512
    [No Abstract]   [Full Text] [Related]  

  • 7. New drug approval times and clinical evidence in Japan.
    Ono S; Yoshioka C; Asaka O; Tamura K; Shibata T; Saito K
    Contemp Clin Trials; 2005 Dec; 26(6):660-72. PubMed ID: 16122988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications.
    Paczynski RP; Alexander GC; Chinchilli VM; Kruszewski SP
    Int J Risk Saf Med; 2012 Jan; 24(3):137-46. PubMed ID: 22936056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Off-label prescription of drugs in the statutory health insurance].
    Niederauer HH
    Gesundheitswesen; 2010 Feb; 72(2):116-9. PubMed ID: 19894208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Solutions for off-label therapy].
    Schmidt WA
    Z Rheumatol; 2003; 62(Suppl 2):II54-6. PubMed ID: 14648094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
    Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
    Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Legal decisions of german supreme courts about prescription of drugs for not registered indications ("off-label-use")].
    Wetterling T
    Fortschr Neurol Psychiatr; 2004 May; 72(5):255-9. PubMed ID: 15136946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viagra's rise above women's health issues: an analysis of the social and political influences on drug approvals in the United States and Japan.
    Hollander I
    Soc Sci Med; 2006 Feb; 62(3):683-93. PubMed ID: 16040176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cannabis in medicine. Legal aspects].
    Wartensleben H
    Schmerz; 2004 Dec; 18 Suppl 2():S34-5. PubMed ID: 23570089
    [No Abstract]   [Full Text] [Related]  

  • 17. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated approval of oncology products: a decade of experience.
    Dagher R; Johnson J; Williams G; Keegan P; Pazdur R
    J Natl Cancer Inst; 2004 Oct; 96(20):1500-9. PubMed ID: 15494600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Review process of new oncology drug application in Japan--role of MD reviewer].
    Fujiwara Y
    Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):196-203. PubMed ID: 9987519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteriation of clinical data packages using foreign data in new drug applications in Japan.
    Tanaka M; Nagata T
    Clin Pharmacol Ther; 2008 Sep; 84(3):340-6. PubMed ID: 17786162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.